RUNX2 and hepatocellular carcinoma: NUPR1 suppression increased the sensitivity of HCC cells to sorafenib (an effective therapeutic for HCC) and regulated a variety of important genes in HCC development such as TGFB2, FGF19, BMP7, and RUNX2 [78].